SARS-CoV-2 vaccination in haemodialysis patients: Insides from a prospective study comparing mRNA and viral vector vaccines

Louise Füessler and Ulf Schönernarck *

Department of Medicine IV, University Hospital, LMU Munich

Nearly three years into the pandemic, COVID-19 has led to vast changes in our lives, having a large impact on morbidity and mortality especially among vulnerable patient populations such as those with end-stage kidney disease.1 We have witnessed the rise of unprecedented vaccines developed with the combined effort of the medical society in no time. Overall, they contributed to reduce morbidity and mortality. Clinical approval studies however excluded high-risk populations such as hemodialysis patients. So far, only smaller studies have investigated either humoral antibody response or clinical effectiveness after SARS-CoV-2 vaccination within this group. Larger cohorts simultaneously analyzing serological and clinical effectiveness especially after the application of different vaccine types are still needed.

In the current issue of The Lancet Regional Health – Europe, Martin and colleagues2 report the results of a prospective observational study which compared the immunogenicity and clinical effectiveness of two doses of mRNA-based (BNT162b2) versus two doses of viral vector (ChAdOx1) SARS-CoV-2 vaccines within a large cohort of 1021 haemodialysis patients in the UK. 523 (51%) patients received BNT162b and 498 (49%) patients received ChAdOx1. Almost half of the patients (45.7%) had evidence of prior infection before vaccination. Humoral response was assessed with measurement of anti-spike antibodies; T cell response was analyzed in a subgroup of 191 patients (19%). During the study period, rigorous testing was performed with weekly nasopharyngeal swab PCR tests and anti-nucleocapsid serology to detect breakthrough infections. 84 patients who refused vaccination served as a reference group. Serological responses after a third booster vaccination with BNT162b2 were assessed in 507 patients without breakthrough infections.

The study is one of the largest to compare viral vector and mRNA vaccines against SARS-CoV-2 in haemodialysis patients. Its particular strength lies in the combination of antibody measurement and rigorous COVID-19 infection monitoring to establish vaccine effectiveness. The study found comparable high seroconversion rates of 91.7% between both vaccine types. Overall T cell response was poor. Previous COVID-19 infection was associated with significantly higher antibody response, immunosuppressive treatment with lower antibody concentrations. These results support the findings of numerous smaller studies using mostly mRNA vaccines in haemodialysis patients: a favorable, albeit diminished early antibody response with lower antibody levels compared to healthy controls; higher antibody levels in patients with previous COVID-19 infection and an inverse correlation with systemic immunosuppression; higher antibody levels with mRNA vaccines (mRNA-1273 > BNT162b2 > ChAdOx1); declining antibody titres within 6 months of vaccination, and a good response after booster vaccinations.2

Although ChAdOx1 led to significantly lower anti-spike antibody levels, both BNT162b2 and ChAdOx1 vaccines showed comparable clinical benefit, with high effectiveness in preventing hospitalization by 77% (rate per 1000-patient days: 0.33 vs. 0.09) and death by 93% (rate per 1000-patient days: 0.22 vs. 0.038) related to COVID-19 in the real-world setting. These results go in line with previous studies.3 Vaccine effectiveness to prevent an infection was expectedly lower (53%). Patients with low or without antibody response after the second vaccine dose were at higher risk of breakthrough infections as reported by others.4

Anti-spike antibody titres significantly increased after a third mRNA booster vaccination which has been confirmed by several studies.5-7 Antibody titres remained significantly higher after homologous mRNA vaccination compared to heterologous vaccination. A first SARS-CoV-2 booster significantly increases the humoral antibody response in hemodialysis patients as well as in the general population and is now considered an essential part of the vaccine strategy.1

DOI of original article: http://dx.doi.org/10.1016/j.lanepe.2022.100478

*Corresponding author at: Department of Medicine IV, University Hospital, LMU Munich, Marchioninistrasse 15, D-81377 Munich, Germany.

E-mail address: Ulf.Schoenermarck@med.uni-muenchen.de (U. Schönernarck).

© 2022 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

www.thelancet.com Vol 21 October, 2022
The following decline in antibody titres can be successfully reversed with a second booster dose. Nevertheless, adaptation of vaccine strategies for haemodialysis patients is warranted. Patients with prior COVID-19 infection elicit significantly higher antibody responses. In this case, a booster vaccination could be postponed, whereas patients with poor antibody response might benefit from earlier booster vaccinations. This argues in favor of regular assessment of quantitative antibody titres, while further studies need to establish protective antibody thresholds.

However, with the emergence of new virus variants the picture has changed. The Omicron variant has demonstrated significant immune evasive properties with higher rates of breakthrough infections despite primary and booster vaccinations. Nonetheless, mortality is significantly lower compared to previous variants. As current vaccines elicit a decreased humoral and cellular immune response against Omicron compared to SARS-CoV-2 wild type even after 4 doses, we are looking forward to the approval of Omicron-adapted SARS-CoV-2 vaccines.

What can we learn for the implementation of other vaccinations in high-risk populations, e.g., patients with end-stage kidney disease or immunosuppressive therapy? Regular assessment of vaccine responses, either using antibody measurement and/or cellular responses should become routine clinical practice. Adopting vaccination strategies with higher vaccine doses or multiple dosing for non-responders should be considered, the latter already having been established for hepatitis B vaccination. Further studies need to determine protective thresholds and booster schedules for COVID-19 and other vaccines, depending on their clinical benefit.

Contributors
Both authors contributed equally to this work.

Declaration of interests
The authors have no competing interests to declare that are relevant to the content of this article.

Funding
This research received no external funding.

References
1. El Karoui K, De Vriese AS. COVID-19 in dialysis: clinical impact, immune response, prevention, and treatment. Kidney Int. 2022;101(9):883–894. https://doi.org/10.1016/j.kint.2022.01.022.
2. Martin P, Gleeson S, Clarke CL, et al. Comparison of immunogenicity and clinical effectiveness between BNT162b2 and ChAdOx1 SARS-CoV-2 vaccines in people with end-stage kidney disease receiving haemodialysis: a prospective, observational cohort study. Lancet Reg Health Eur. 2022;21:100478.
3. Brüll SM, Sibel S, Karpinski S, et al. Comparative effectiveness of mRNA-based BNT162b2 vaccine versus adenovirus vector-based Ad26.COV2.S vaccine for the prevention of COVID-19 among dialysis patients. J Am Soc Nephrol. 2022;33(4):688–697. https://doi.org/10.1681/ASN.2021101595.
4. Boudhpbhay I, Serris A, Servais A, et al. COVID-19 outbreak in vaccinated patients from a haemodialysis unit: antibody titres as a marker of protection from infection. Nephrol Dial Transplant. 2022;37(5):1547–1561. https://doi.org/10.1093/ndt/gfac016.
5. Füssl L, Lai T, Rau S, et al. Humoral response after SARS-CoV-2 booster vaccination in haemodialysis patients with and without prior infection. Clinical Kidney Journal. 2022;15(8):1633–1635. https://doi.org/10.1093/ckj/sfac148.
6. Houset P, Kubab S, Hanafi L, et al. Humoral response after a fourth “booster” dose of a Coronavirus disease 2019 vaccine following a 3-dose regimen of mRNA-based vaccination in dialysis patients. Kidney Int. 2022;101(6):1289–1290. https://doi.org/10.1016/j.kint.2022.04.006.
7. Meijers B, Goedgezelschap A, Peeters D, et al. Heterologous versus homologous triple anti-COVID-19 vaccine regimens in patients on maintenance haemodialysis. Nephrol Dial Transplant. 2021;37(7):1584–1586. https://doi.org/10.1093/ndt/gfac035.
8. Cinklic O, Anft M, Blazquez-Navarro A, et al. Inferior humoral and sustained cellular immunity against wild-type and omicron variant of concern in hemodialysis patients immunized with 3 SARS-CoV-2 vaccine doses compared with 4 doses. Kidney Int. 2022;101(6):1287–1289. https://doi.org/10.1016/j.kint.2022.03.005.
9. Einbinder Y, Perl J, Nacash N, et al. Humoral response and SARS-CoV-2 infection risk following the third and fourth doses of the BNT162b2 vaccine in dialysis patients. Am J Nephrol. 2022;18:1–5. https://doi.org/10.1159/000521200.
10. Anft M, Blazquez-Navarro A, Frahnert M, et al. Inferior cellular and humoral immunity against Omicron and Delta variants of concern compared with SARS-CoV-2 wild type in haemodialysis patients immunized with 4 SARS-CoV-2 vaccine doses. Kidney Int. 2022;102(1):207–208. https://doi.org/10.1016/j.kint.2022.05.004.